legalized gambling canada
TORONTO -- Biovail Corporation (NYSE: BVF) (TSX: BVF) today announced that it has received a Notice of Compliance from the Therapeutic Products Directorate (TPD) for its supplemental New Drug Submission (sNDS) for a new indication for Wellbutrin[R] XL in Canada - the prevention of major depressive illness with an autumn-winter seasonal pattern. The approval of Wellbutrin[R] XL for this indication represents a significant milestone for Biovail and for Canadian healthcare, as it represents the first time in Canada that a medication has received an indication for the prevention of this type of major depressive illness. Many patients with major depressive disorder have a seasonal pattern to their disease. internet gambling research no deposits casino all of them casinos new bonuses slots of fun hot dogs
